Rallybio Corporation (RLYB) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The risk factor highlights that Rallybio Corporation’s CVRs may never deliver value to stockholders, as any payout depends entirely on successful and timely monetization of Legacy Assets and receipt of specified cash proceeds from Recursion Pharmaceuticals under a future agreement. Since the combined company will control if and how these assets are monetized, and the CVRs are unsecured and subordinated to senior obligations, investors bear a significant risk that the CVRs will ultimately expire worthless.
Overall, Wall Street has a Hold consensus rating on RLYB stock based on 1 Hold.
To learn more about Rallybio Corporation’s risk factors, click here.